The U.S. Food and Drug Administration announced a proposed rule on November 16, 2026, that would allow N-acetyl-L-cysteine, or NAC, in otherwise lawful dietary supplements. The proposal would replace an ingredient exclusion with a formal regulatory exception if finalized, giving research institutions and regulatory teams a new policy development to track without changing the status of individual research protocols.
FDA proposes a new exception for NAC
In its November 16 announcement, FDA said the rule would reverse NAC’s exclusion from the statutory definition of a dietary supplement. Products would still have to satisfy the other requirements of the Federal Food, Drug, and Cosmetic Act. The agency describes this as its first use of the rulemaking authority in that exclusion provision.
The public-inspection text would establish 21 CFR 190.1, titled “Dietary ingredients not excluded from the dietary supplement definition,” with NAC as its first listed ingredient. It also addresses the separate prohibition in section 301(ll) concerning the addition of certain drugs to food, including dietary supplements.
The document is scheduled for Federal Register publication on November 17. It is a proposal, rather than a final regulation. FDA’s announcement says the comment period will last 60 days, and the public-inspection text ties that period to publication rather than the November 16 announcement date.
Why a marketed ingredient still needs rulemaking
FDA’s earlier policy announcement explains the underlying distinction. The agency determined that NAC had been approved as a new drug before it was marketed as food or a supplement, bringing it within the statutory exclusion. In 2022, however, FDA adopted enforcement discretion for certain NAC products labeled as dietary supplements that would otherwise comply with the law.
The August 1, 2022 final guidance announcement followed a draft issued in April of that year. It described a temporary enforcement approach while FDA evaluated a petition asking it to undertake rulemaking. An update on November 29, 2023 said the agency had completed its safety-information review and was moving the systematic review into external peer review.
FDA now says it intends to continue that enforcement-discretion policy during rulemaking. This explains why the announcement can concern lawful supplement eligibility even though NAC products have already been sold. Existing market availability and an ingredient’s formal statutory classification are different questions.
What the proposal would and would not establish
Nutritional Outlook’s November 16 report emphasizes that NAC products would remain subject to supplement manufacturing requirements and enforcement against adulterated or misbranded products. The outlet also notes FDA’s proposed immediate effective date for any final rule. That proposed timing does not make the current proposal effective immediately.
Edit USA’s independent report similarly distinguishes the temporary enforcement policy from the regulatory exception FDA now proposes. It explains that the change concerns ingredient eligibility and does not turn supplement labeling into authorization to make disease-treatment claims.
FDA says its comprehensive review did not identify safety concerns for NAC in or as a dietary supplement. That is the agency’s assessment for this regulatory action. It does not establish the effectiveness of a particular research intervention or replace the evidence needed to evaluate a study’s intended use.
FDA’s impact analysis uses the existing market as its baseline
The agency’s preliminary regulatory impact analysis compares the proposed exception with a baseline in which NAC is excluded but certain sales continue under enforcement discretion. It does not treat the rule as creating a supplement market from scratch.
FDA does not quantify benefits in that analysis. It says greater legal clarity could prompt new products, but the likelihood and scale of those effects are difficult to estimate. Its modeled costs concern manufacturers reading and understanding the rule. Those estimates concern regulatory familiarization rather than a comprehensive budget for research, product testing or manufacturing compliance.
The analysis also considers an alternative that would delay a final rule’s effective date by one year. Presenting that alternative alongside the proposed immediate date makes implementation timing an explicit part of the policy discussion. Neither option is an announced date for finalization.
What research offices can take from the announcement
For university regulatory affairs teams, the practical development is a possible change in ingredient classification. As an editorial implication, institutional summaries should distinguish the proposed rule, the continuing enforcement policy and any eventual final rule. Recording the document and its date avoids treating those three stages as interchangeable.
Research teams should also keep a product’s marketing category separate from the question posed by a study. The investigational new drug framework concerns research authorization; this proposal addresses the dietary supplement definition. FDA’s notice does not purport to approve a university protocol or establish a study-specific exemption. Institutions assessing a project still need to consider its actual design and intended use.
The relevant documentary trail includes the proposal, the earlier guidance and the impact analysis. CASRAI’s guide to finding and citing FDA guidance provides background on keeping guidance documents identifiable alongside regulatory materials. Here, FDA is expressly pursuing notice-and-comment rulemaking after years of using guidance to describe its enforcement policy.
What happens next
Comments belong in docket FDA-2025-N-2699. The public-inspection notice says electronic comments and attachments will be posted publicly as submitted, and it provides separate paper-submission instructions for confidential information. Research institutions preparing submissions can use those instructions to separate publishable evidence from confidential material.
The next dated step is the scheduled November 17 publication, followed by the 60-day comment period. FDA says existing enforcement discretion continues while that process proceeds. A final decision, and the terms of any final regulation, remain separate steps.
Sources
- FDA, NAC proposed-rule announcement, November 16, 2026; checked 2026-11-16.
- FDA/Federal Register, proposed rule, docket FDA-2025-N-2699, filed November 16, 2026, scheduled publication November 17; checked 2026-11-16.
- FDA, enforcement-discretion guidance announcement, August 1, 2022, with November 29, 2023 update; checked 2026-11-16.
- FDA, preliminary regulatory impact analysis, associated with the proposal; checked 2026-11-16.
- Nutritional Outlook, FDA proposes rule to allow NAC as a dietary supplement ingredient, November 16, 2026; checked 2026-11-16.
- Edit USA, FDA proposes allowing NAC in dietary supplements, November 16, 2026; checked 2026-11-16.







